Contact Us
Schwab Client Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

195.09 -0.94 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 838,177
Open 197.68
Bid (Size) 195.09 (200)
Ask (Size) 195.18 (300)
Prev. Close 196.03
Today's Range 194.35 - 201.42
52wk Range 115.31 - 260.19
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction ↗
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in... 
Via MarketBeat

Performance

YTD
+9.2%
+9.2%
1 Month
-5.1%
-5.1%
3 Month
-17.8%
-17.8%
6 Month
+18.8%
+18.8%
1 Year
+64.3%
+64.3%

More News

Read More
News headline image
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference ↗
Via MarketBeat
News headline image
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Is Axsome Therapeutics a Buy on the Dip? ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗
Via Benzinga
News headline image
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗
Via Benzinga
News headline image
Axsome Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Better Growth Buy: Axsome vs Revolution Medicines ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 195.09
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 09/25/26 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 9.21B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.